Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis.
Eur J Gastroenterol Hepatol
; 33(1S Suppl 1): e1057-e1059, 2021 12 01.
Article
em En
| MEDLINE
| ID: mdl-34074983
ABSTRACT
Vedolizumab, an anti-integrin antibody, is effective for moderate to severe ulcerative colitis and Crohn's disease treatment with a good safety profile due to its gut selective mechanism of action. Upper respiratory tract vedolizumab adverse events are common; however, they are mild and do not require treatment withdrawal. Herein, we present a 39-year-old patient under vedolizumab treatment for ulcerative colitis who presented acute severe interstitial lung injury that necessitated vedolizumab withdrawal and systemic steroids administration.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Colite Ulcerativa
/
Lesão Pulmonar
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article